The Medicinal Cannabis (R)evolution

17

Canada and Australia. Indeed, given the fragmented legislation across countries, there is still much uncertainty surrounding medicinal cannabis market and the degree of openness by countries stemming from increasing concerns for medical grade cannabis (Jelsma et al., 2019). To capitalize on these markets, industry stakeholders will be required to comply with country-level standards such as Good Agricultural Practices (GAP), Good Agricultural and Collection Practices, Good Laboratory Practices (GLP) and Good Manufacturing Practices. Compliance to these standards and best practices would increase opportunities for global export and ensures that production and testing are appropriate for the production of pharmaceuticals that would prevent harm to end users.